In April 2025, Novartis announced plans to invest $23 billion into its US-based infrastructure, including the creation of a premiere, state-of-the-art Biomedical Research hub in San Diego. The $1.1 ...

Sie suchen Kreativität und Innovation? Novartis bietet Ihnen das nötige Umfeld! Menschen, die uns mit ihrem Können und ihrer Erfahrung weiterbringen, können das Gleiche auch von uns erwarten. Think ...

Novartis has been serving patients in Indonesia for more than 50 years, through our predecessor companies, Ciba and Sandoz.

Sie suchen Kreativität und Innovation? Novartis bietet Ihnen das nötige Umfeld! Menschen, die uns mit ihrem Können und ihrer Erfahrung weiterbringen, können das Gleiche auch von uns erwarten. Think ...

Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.

A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Iptacopan in Patients With Generalized Myasthenia Gravis (gMG), Followed by an Open ...

Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.

The purpose of this study is to evaluate the efficacy and safety of AAA617 alone (Lutetium \ [177Lu\] vipivotide tetraxetan) and in combination with an Androgen Receptor Pathway Inhibitors (ARPI) in ...

Leader mondial dans le domaine de la santé, Novartis propose actuellement l’un des portefeuilles les plus complets du marché. Un portefeuille de médicaments innovants, développés par des personnes ...

Ianalumab prolonged the duration of safe platelet levels during and after treatment in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids1,2 Patients treated ...